LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Karwi, Qutuba; Whiteman, Matthew; Wood, Mark E.; Torregrossa, Roberta; Baxter, Gary (2016)
Publisher: Elsevier
Languages: English
Types: Article
Subjects:
Exogenous hydrogen sulfide (H2S) protects against myocardial ischemia/reperfusion injury but the mechanism of action is unclear. The present study investigated the effect of GYY4137, a slow-releasing H2S donor, on myocardial infarction given specifically at reperfusion and the signalling pathway involved. Thiobutabarbital-anesthetised rats were subjected to 30min of left coronary artery occlusion and 2h reperfusion. Infarct size was assessed by tetrazolium staining. In the first study, animals randomly received either no treatment or GYY4137 (26.6, 133 or 266μmolkg-1) by intravenous injection 10min before reperfusion. In a second series, involvement of PI3K and NO signalling were interrogated by concomitant administration of LY294002 or L-NAME respectively and the effects on the phosphorylation of Akt, eNOS, GSK-3β and ERK1/2 during early reperfusion were assessed by immunoblotting. GYY4137 266μmolkg-1 significantly limited infarct size by 47% compared to control hearts (P<0.01). In GYY4137-treated hearts, phosphorylation of Akt, eNOS and GSK-3β was increased 2.8, 2.2 and 2.2 fold respectively at early reperfusion. Co-administration of L-NAME and GYY4137 attenuated the cardioprotection afforded by GYY4137, associated with attenuated phosphorylation of eNOS. LY294002 totally abrogated the infarct-limiting effect of GYY4137 and inhibited Akt, eNOS and GSK-3β phosphorylation. These data are the first to demonstrate that GYY4137 protects the heart against lethal reperfusion injury through activation of PI3K/Akt signalling, with partial dependency on NO signalling and inhibition of GSK-3β during early reperfusion. H2S-based therapeutic approaches may have value as adjuncts to reperfusion in the treatment of acute myocardial infarction.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • ALEXANDER, B. E., COLES, S. J., FOX, B. C., KHAN, T. F., MALISZEWSKI, J., PERRY, A., PITAK, M. B., WHITEMAN, M. & WOOD, M. E. 2015. Investigating the generation of hydrogen sulfide from the phosphonamidodithioate slow-release donor GYY4137. Medicinal Chemical Communications, 6, 1649-1655.
    • BARSUKEVICH, V., BASALAY, M., SANCHEZ, J., MROCHEK, A., WHITTLE, J., ACKLAND, G. L., GOURINE, A. V. & GOURINE, A. 2015. Distinct cardioprotective mechanisms of immediate, early and delayed ischaemic postconditioning. Basic Res Cardiol, 110, 452.
    • BIAN, J. S., YONG, Q. C., PAN, T. T., FENG, Z. N., ALI, M. Y., ZHOU, S. & MOORE, P. K. 2006. Role of hydrogen sulfide in the cardioprotection caused by ischemic preconditioning in the rat heart and cardiac myocytes. J Pharmacol Exp Ther, 316, 670-8.
    • BIBLI, S. I., ANDREADOU, I., CHATZIANASTASIOU, A., TZIMAS, C., SANOUDOU, D., KRANIAS, E., BROUCKAERT, P., COLETTA, C., SZABO, C., KREMASTINOS, D. T., ILIODROMITIS, E. K. & PAPAPETROPOULOS, A. 2015. Cardioprotection by H2S engages a cGMP-dependent protein kinase G/phospholamban pathway. Cardiovasc Res, 106, 432-42.
    • BURLEY, D. S. & BAXTER, G. F. 2009. Pharmacological targets revealed by myocardial postconditioning. Curr Opin Pharmacol, 9, 177-88.
    • BURLEY, D. S., FERDINANDY, P. & BAXTER, G. F. 2007. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol, 152, 855-69.
    • CABRERA-FUENTES, H. A., ALBA-ALBA, C., ARAGONES, J., BERNHAGEN, J., BOISVERT, W. A., BOTKER, H. E., CESARMAN-MAUS, G., FLEMING, I., GARCIA-DORADO, D., LECOUR, S., LIEHN, E., MARBER, M. S., MARINA, N., MAYR, M., PEREZ-MENDEZ, O., MIURA, T., RUIZ-MEANA, M., SALINAS-ESTEFANON, E. M., ONG, S. B., SCHNITTLER, H. J., SANCHEZVEGA, J. T., SUMOZA-TOLEDO, A., VOGEL, C. W., YARULLINA, D., YELLON, D. M., PREISSNER, K. T. & HAUSENLOY, D. J. 2016. Meeting report from the 2nd International Symposium on New Frontiers in Cardiovascular Research. Protecting the cardiovascular system from ischemia: between bench and bedside. Basic Res Cardiol, 111, 7.
    • CALVERT, J. W., JHA, S., GUNDEWAR, S., ELROD, J. W., RAMACHANDRAN, A., PATTILLO, C. B., KEVIL, C. G. & LEFER, D. J. 2009. Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ Res, 105, 365-74.
    • CHUAH, S. C., MOORE, P. K. & ZHU, Y. Z. 2007. S-allylcysteine mediates cardioprotection in an acute myocardial infarction rat model via a hydrogen sulfide-mediated pathway. Am J Physiol Heart Circ Physiol, 293, H2693-701.
    • DAS, A., SAMIDURAI, A., HOKE, N. N., KUKREJA, R. C. & SALLOUM, F. N. 2015. Hydrogen sulfide mediates the cardioprotective effects of gene therapy with PKG-Ialpha. Basic Res Cardiol, 110, 42.
    • ELROD, J. W., CALVERT, J. W., MORRISON, J., DOELLER, J. E., KRAUS, D. W., TAO, L., JIAO, X., SCALIA, R., KISS, L., SZABO, C., KIMURA, H., CHOW, C. W. & LEFER, D. J. 2007. Hydrogen sulfide attenuates myocardial ischemiareperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci U S A, 104, 15560-5.
    • FERDINANDY, P., HAUSENLOY, D. J., HEUSCH, G., BAXTER, G. F. & SCHULZ, R. 2014. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev, 66, 1142-74.
    • FOX, B., SCHANTZ, J. T., HAIGH, R., WOOD, M. E., MOORE, P. K., VINER, N., SPENCER, J. P., WINYARD, P. G. & WHITEMAN, M. 2012. Inducible hydrogen sulfide synthesis in chondrocytes and mesenchymal progenitor cells: is H2S a novel cytoprotective mediator in the inflamed joint? J Cell Mol Med, 16, 896-910.
    • FRADORF, J., HUHN, R., WEBER, N. C., EBEL, D., WINGERT, N., PRECKEL, B., TOMA, O., SCHLACK, W. & HOLLMANN, M. W. 2010. Sevoflurane-induced preconditioning: impact of protocol and aprotinin administration on infarct size and endothelial nitric-oxide synthase phosphorylation in the rat heart in vivo. Anesthesiology, 113, 1289-98.
    • GRAMBOW, E., MUELLER-GRAF, F., DELYAGINA, E., FRANK, M., KUHLA, A. & VOLLMAR, B. 2014. Effect of the hydrogen sulfide donor GYY4137 on platelet activation and microvascular thrombus formation in mice. Platelets, 25, 166-74.
    • HACKFORT, B. T. & MISHRA, P. K. 2016. Emerging role of hydrogen sulfidemicroRNA cross-talk in cardiovascular diseases. Am J Physiol Heart Circ Physiol, ajpheart 00660 2015.
    • HAN, S. J., KIM, J. I., PARK, J. W. & PARK, K. M. 2015. Hydrogen sulfide accelerates the recovery of kidney tubules after renal ischemia/reperfusion injury. Nephrol Dial Transplant, 30, 1497-506.
    • HAUSENLOY, D. J., ONG, S. B. & YELLON, D. M. 2009. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol, 104, 189-202.
    • HAUSENLOY, D. J. & YELLON, D. M. 2007. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev, 12, 217-34.
    • HUANG, Y. E., TANG, Z. H., XIE, W., SHEN, X. T., LIU, M. H., PENG, X. P., ZHAO, Z. Z., NIE, D. B., LIU, L. S. & JIANG, Z. S. 2012. Endogenous hydrogen sulfide mediates the cardioprotection induced by ischemic postconditioning in the early reperfusion phase. Exp Ther Med, 4, 1117-1123.
    • IMANI, A., FAGHIHI, M., SADR, S. S., NIARAKI, S. S. & ALIZADEH, A. M. 2011. Noradrenaline protects in vivo rat heart against infarction and ventricular arrhythmias via nitric oxide and reactive oxygen species. J Surg Res, 169, 9- 15.
    • ISLAM, K. N., POLHEMUS, D. J., DONNARUMMA, E., BREWSTER, L. P. & LEFER, D. J. 2015. Hydrogen Sulfide Levels and Nuclear Factor-Erythroid 2-Related Factor 2 (NRF2) Activity Are Attenuated in the Setting of Critical Limb Ischemia (CLI). J Am Heart Assoc, 4.
    • JAMROZ-WISNIEWSKA, A., GERTLER, A., SOLOMON, G., WOOD, M. E., WHITEMAN, M. & BELTOWSKI, J. 2014. Leptin-induced endotheliumdependent vasorelaxation of peripheral arteries in lean and obese rats: role of nitric oxide and hydrogen sulfide. PLoS One, 9, e86744.
    • JOHANSEN, D., YTREHUS, K. & BAXTER, G. F. 2006. Exogenous hydrogen sulfide (H2S) protects against regional myocardial ischemia-reperfusion injury-- Evidence for a role of K ATP channels. Basic Res Cardiol, 101, 53-60.
    • KILKENNY, C., BROWNE, W., CUTHILL, I. C., EMERSON, M., ALTMAN, D. G. & GROUP, N. C. R. R. G. W. 2010. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol, 160, 1577-9.
    • KING, A. L., POLHEMUS, D. J., BHUSHAN, S., OTSUKA, H., KONDO, K., NICHOLSON, C. K., BRADLEY, J. M., ISLAM, K. N., CALVERT, J. W., TAO, Y. X., DUGAS, T. R., KELLEY, E. E., ELROD, J. W., HUANG, P. L., WANG, R. & LEFER, D. J. 2014. Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide dependent. Proc Natl Acad Sci U S A, 111, 3182-7.
    • KONDO, K., BHUSHAN, S., KING, A. L., PRABHU, S. D., HAMID, T., KOENIG, S., MUROHARA, T., PREDMORE, B. L., GOJON, G., SR., GOJON, G., JR., WANG, R., KARUSULA, N., NICHOLSON, C. K., CALVERT, J. W. & LEFER, D. J. 2013. H(2)S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase. Circulation, 127, 1116-27.
    • LAMBERT, J. P., NICHOLSON, C. K., AMIN, H., AMIN, S. & CALVERT, J. W. 2014. Hydrogen sulfide provides cardioprotection against myocardial/ischemia reperfusion injury in the diabetic state through the activation of the RISK pathway. Med Gas Res, 4, 20.
    • LEE, Z. W., ZHOU, J., CHEN, C. S., ZHAO, Y., TAN, C. H., LI, L., MOORE, P. K. & DENG, L. W. 2011. The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One, 6, e21077.
    • LI, H., WANG, Y., WEI, C., BAI, S., ZHAO, Y., LI, H., WU, B., WANG, R., WU, L. & XU, C. 2015a. Mediation of exogenous hydrogen sulfide in recovery of ischemic post-conditioning-induced cardioprotection via down-regulating oxidative stress and up-regulating PI3K/Akt/GSK-3beta pathway in isolated aging rat hearts. Cell Biosci, 5, 11.
    • LI, H., ZHANG, C., SUN, W., LI, L., WU, B., BAI, S., LI, H., ZHONG, X., WANG, R., WU, L. & XU, C. 2015b. Exogenous hydrogen sulfide restores cardioprotection of ischemic post-conditioning via inhibition of mPTP opening in the aging cardiomyocytes. Cell Biosci, 5, 43.
    • LI, L., SALTO-TELLEZ, M., TAN, C. H., WHITEMAN, M. & MOORE, P. K. 2009. GYY4137, a novel hydrogen sulfide-releasing molecule, protects against endotoxic shock in the rat. Free Radic Biol Med, 47, 103-13.
    • LI, L., WHITEMAN, M., GUAN, Y. Y., NEO, K. L., CHENG, Y., LEE, S. W., ZHAO, Y., BASKAR, R., TAN, C. H. & MOORE, P. K. 2008. Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. Circulation, 117, 2351-60.
    • LISJAK, M., SRIVASTAVA, N., TEKLIC, T., CIVALE, L., LEWANDOWSKI, K., WILSON, I., WOOD, M. E., WHITEMAN, M. & HANCOCK, J. T. 2010. A novel hydrogen sulfide donor causes stomatal opening and reduces nitric oxide accumulation. Plant Physiol Biochem, 48, 931-5.
    • LIU, Y. H., LU, M., HU, L. F., WONG, P. T., WEBB, G. D. & BIAN, J. S. 2012. Hydrogen sulfide in the mammalian cardiovascular system. Antioxid Redox Signal, 17, 141-85.
    • LIU, Z., HAN, Y., LI, L., LU, H., MENG, G., LI, X., SHIRHAN, M., PEH, M. T., XIE, L., ZHOU, S., WANG, X., CHEN, Q., DAI, W., TAN, C. H., PAN, S., MOORE, P. K. & JI, Y. 2013. The hydrogen sulfide donor, GYY4137, exhibits antiatherosclerotic activity in high fat fed apolipoprotein E(-/-) mice. Br J Pharmacol, 169, 1795-809.
    • MCGRATH, J. C., DRUMMOND, G. B., MCLACHLAN, E. M., KILKENNY, C. & WAINWRIGHT, C. L. 2010. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol, 160, 1573-6.
    • MENG, G., WANG, J., XIAO, Y., BAI, W., XIE, L., SHAN, L., MOORE, P. K. & JI, Y. 2015a. GYY4137 protects against myocardial ischemia and reperfusion injury by attenuating oxidative stress and apoptosis in rats. J Biomed Res, 29, 203- 13.
    • MENG, G., ZHU, J., XIAO, Y., HUANG, Z., ZHANG, Y., TANG, X., XIE, L., CHEN, Y., SHAO, Y., FERRO, A., WANG, R., MOORE, P. K. & JI, Y. 2015b. Hydrogen Sulfide Donor GYY4137 Protects against Myocardial Fibrosis. Oxid Med Cell Longev, 2015, 691070.
    • PAN, T. T., CHEN, Y. Q. & BIAN, J. S. 2009. All in the timing: a comparison between the cardioprotection induced by H2S preconditioning and post-infarction treatment. Eur J Pharmacol, 616, 160-5.
    • PAPAPETROPOULOS, A., WHITEMAN, M. & CIRINO, G. 2015. Pharmacological tools for hydrogen sulphide research: a brief, introductory guide for beginners. Br J Pharmacol, 172, 1633-7.
    • POLHEMUS, D. J., LI, Z., PATTILLO, C. B., GOJON, G., SR., GOJON, G., JR., GIORDANO, T. & KRUM, H. 2015. A novel hydrogen sulfide prodrug, SG1002, promotes hydrogen sulfide and nitric oxide bioavailability in heart failure patients. Cardiovasc Ther, 33, 216-26.
    • PREDMORE, B. L., KONDO, K., BHUSHAN, S., ZLATOPOLSKY, M. A., KING, A. L., ARAGON, J. P., GRINSFELDER, D. B., CONDIT, M. E. & LEFER, D. J. 2012. The polysulfide diallyl trisulfide protects the ischemic myocardium by preservation of endogenous hydrogen sulfide and increasing nitric oxide bioavailability. Am J Physiol Heart Circ Physiol, 302, H2410-8.
    • ROBINSON, H. & WRAY, S. 2012. A new slow releasing, H(2)S generating compound, GYY4137 relaxes spontaneous and oxytocin-stimulated contractions of human and rat pregnant myometrium. PLoS One, 7, e46278.
    • ROSSONI, G., SPARATORE, A., TAZZARI, V., MANFREDI, B., DEL SOLDATO, P. & BERTI, F. 2008. The hydrogen sulphide-releasing derivative of diclofenac protects against ischaemia-reperfusion injury in the isolated rabbit heart. Br J Pharmacol, 153, 100-9.
    • SIVARAJAH, A., COLLINO, M., YASIN, M., BENETTI, E., GALLICCHIO, M., MAZZON, E., CUZZOCREA, S., FANTOZZI, R. & THIEMERMANN, C. 2009. Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock, 31, 267-74.
    • SLUIJTER, J. P., CONDORELLI, G., DAVIDSON, S. M., ENGEL, F. B., FERDINANDY, P., HAUSENLOY, D. J., LECOUR, S., MADONNA, R., OVIZE, M., RUIZ-MEANA, M., SCHULZ, R., VAN LAAKE, L. W. & NUCLEUS OF THE EUROPEAN SOCIETY OF CARDIOLOGY WORKING GROUP CELLULAR BIOLOGY OF THE, H. 2014. Novel therapeutic strategies for cardioprotection. Pharmacol Ther, 144, 60-70.
    • SODHA, N. R., CLEMENTS, R. T., FENG, J., LIU, Y., BIANCHI, C., HORVATH, E. M., SZABO, C., STAHL, G. L. & SELLKE, F. W. 2009. Hydrogen sulfide therapy attenuates the inflammatory response in a porcine model of myocardial ischemia/reperfusion injury. J Thorac Cardiovasc Surg, 138, 977- 84.
    • SOJITRA, B., BULANI, Y., PUTCHA, U. K., KANWAL, A., GUPTA, P., KUNCHA, M. & BANERJEE, S. K. 2012. Nitric oxide synthase inhibition abrogates hydrogen sulfide-induced cardioprotection in mice. Mol Cell Biochem, 360, 61- 9.
    • SUVEREN, E., WHITEMAN, M. & BAXTER, G. F. 2012. The cardioprotective effect of GYY4137, a novel H2S donor, in ischaemia reperfusion injury. Cardiovascular Research, 93, S111-S111.
    • VANDIVER, M. & SNYDER, S. H. 2012. Hydrogen sulfide: a gasotransmitter of clinical relevance. J Mol Med (Berl), 90, 255-63.
    • WANG, J., YANG, H., HU, X., FU, W., XIE, J., ZHOU, X., XU, W. & JIANG, H. 2013. Dobutamine-mediated heme oxygenase-1 induction via PI3K and p38 MAPK inhibits high mobility group box 1 protein release and attenuates rat myocardial ischemia/reperfusion injury in vivo. J Surg Res, 183, 509-16.
    • WHITEMAN, M., LI, L., ROSE, P., TAN, C. H., PARKINSON, D. B. & MOORE, P. K. 2010. The effect of hydrogen sulfide donors on lipopolysaccharide-induced formation of inflammatory mediators in macrophages. Antioxid Redox Signal, 12, 1147-54.
    • YAO, L. L., HUANG, X. W., WANG, Y. G., CAO, Y. X., ZHANG, C. C. & ZHU, Y. C. 2010. Hydrogen sulfide protects cardiomyocytes from hypoxia/reoxygenationinduced apoptosis by preventing GSK-3beta-dependent opening of mPTP. Am J Physiol Heart Circ Physiol, 298, H1310-9.
    • YAO, X., TAN, G., HE, C., GAO, Y., PAN, S., JIANG, H., ZHANG, Y. & SUN, X. 2012. Hydrogen sulfide protects cardiomyocytes from myocardial ischemiareperfusion injury by enhancing phosphorylation of apoptosis repressor with caspase recruitment domain. Tohoku J Exp Med, 226, 275-85.
    • YONG, Q. C., LEE, S. W., FOO, C. S., NEO, K. L., CHEN, X. & BIAN, J. S. 2008. Endogenous hydrogen sulphide mediates the cardioprotection induced by ischemic postconditioning. Am J Physiol Heart Circ Physiol, 295, H1330- H1340.
    • ZHANG, W. J., SHI, Z. X., WANG, B. B., CUI, Y. J., GUO, J. Z. & LI, B. 2001. Allitridum mimics effect of ischemic preconditioning by activation of protein kinase C. Acta Pharmacol Sin, 22, 132-6.
    • ZHAO, Z. Q., CORVERA, J. S., HALKOS, M. E., KERENDI, F., WANG, N. P., GUYTON, R. A. & VINTEN-JOHANSEN, J. 2003. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol, 285, H579-88.
    • ZHUO, Y., CHEN, P. F., ZHANG, A. Z., ZHONG, H., CHEN, C. Q. & ZHU, Y. Z. 2009. Cardioprotective effect of hydrogen sulfide in ischemic reperfusion experimental rats and its influence on expression of survivin gene. Biol Pharm Bull, 32, 1406-10.
    • e r 40 iz t ) k s 50 i
  • No similar publications.

Share - Bookmark

Cite this article